Salivary immunoglobulin A antibodies to gp41 in human immunodeficiency virus-seropositive patients: Lack of correlation with disease progression

Oral Microbiology and Immunology

Volumn 16, Issue 3, 2001, Pages 188-192

  Toro, M J ^a   Escalona, L ^c   Chaiyarit, P ^a   Warner, N A ^a,b   Gregory, R L ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Antibodies; gp41; HIV; Periodontal disease

Indexed keywords

GLYCOPROTEIN GP 41; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANALYSIS OF VARIANCE; ANTIBODY PRODUCTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CLASSIFICATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; SALIVA; SERODIAGNOSIS; WESTERN BLOTTING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; IMMUNOGLOBULIN A, SECRETORY; MALE; SALIVA;

EID: 0035025490     PISSN: 09020055     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-302X.2001.016003188.x     Document Type: Article

References (36)

1. Induction of anti-gp 160 cytotoxic cells cross-reacting with various V3 loop peptides in human immunodeficiency virus type 1 envelope-immunized individuals
2. Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complex
3. In vitro inhibition of HIV-1 infectivity by human salivas
4. Salivary detection of HIV-1 antibodies using recombinant HIV-1 peptides
5. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes
6. Antigen-antibody interactions and monoclonal antibody
7. IgA immunity in HIV type 1-chimpanzees. II. Mucosal immunity
8. Salivary and mucosal immune response to HIV and its copathogens
9. Assessing mucosal humoral immunity
10. Localization of B-cell stimulatory activity of HIV to the carboxyl terminus of gp41
11. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: Its deletions leads to a strong neutralizing response
12. The biological role and clinical implications of IgA
13. Humoral immunity to HIV, SIV, and SHIV
14. Replication and pathogenesis of AIDS virus
15. Secretory and serum IgA are inversely altered in AIDS patients
16. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons
17. Pathogenesis of human immunodeficiency virus infection
18. Rapid and constant detection of HIV antibody response in saliva of HIV-infected patients selective distribution of anti-HIV activity in the IgG isotype
19. Endoproteolytic cleavage of gp 160 is required for the activation of human immunodeficiency virus
20. Immunogenicity of full length and truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein
21. Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs
22. Immunological markers of disease progression in patients infected with human immunodeficiency virus infection
23. CD8 lymphocyte counts and serum IgA levels early in HIV infection as predictor of CD4 lymphocyte depletion during 8 years of follow-up
24. Early impairment of gut mucosal immunity in HIV-1-infected children
25. + T lymphocyte lines from HIV-1 seropositive patients
26. Immunopathogenic mechanisms of HIV infection: Cytokine induction of HIV expression
27. Current concepts in human inmmunodeficiency virus infection and AIDS
28. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation
29. Endogenous mucosal antiviral factors of the oral cavity
30. Salivary sIgA response in HIV-1 infection
31. Human monoclonal antibody against glycoproteins of human immunodeficiency virus
32. IgA subclasses in HIV disease: Dichotomy between raised levels in serum and decreased secretion rates in saliva
33. Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients
34. Salivary immunoglobulin levels and antibodies to Streptococcus mutans in AIDS
35. Clinical detection and diagnosis of human inmunodeficiency virus infection
36. Functional interaction between the cytoplasmic leucinezipper domain of HIV-1 gp41 and p115-RhoGEF